vTv Therapeutics (VTVT) Releases Earnings Results, Beats Estimates By $0.06 EPS

vTv Therapeutics (NASDAQ:VTVT) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06, Fidelity Earnings reports. The business had revenue of $3.38 million for the quarter, compared to analyst estimates of $2.06 million.

vTv Therapeutics stock opened at $2.63 on Friday. vTv Therapeutics has a 52 week low of $0.65 and a 52 week high of $8.40. The firm has a market cap of $91.52 million, a PE ratio of -1.57 and a beta of -3.71.

In other vTv Therapeutics news, major shareholder Ronald O. Perelman purchased 1,879,699 shares of the stock in a transaction dated Tuesday, November 6th. The stock was bought at an average price of $1.33 per share, with a total value of $2,499,999.67. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have bought a total of 5,644,097 shares of company stock valued at $7,504,999 in the last three months. 2.00% of the stock is owned by insiders.

Separately, Zacks Investment Research cut vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $13.29.

WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/11/10/vtv-therapeutics-vtvt-releases-earnings-results-beats-estimates-by-0-06-eps.html.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Featured Article: Discount Rate

Earnings History for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit